Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme

Investigational New Drugs

Volumn 24, Issue 3, 2006, Pages 177-180

  Farray, Daniel ^a   Ahluwalia, Manmeet S ^b   Snyder, Josette ^c   Barnett, Gene H ^c   Cohen, Bruce H ^c   Suh, John H ^c   Peereboom, David M ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Camptothecin; Chemotherapy; Glioblastoma multiforme; High grade astrocytomas

Indexed keywords

9 AMINOCAMPTOTHECIN; LIVER ENZYME; PHENYTOIN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; ERYTHEMA MULTIFORME; FEBRILE NEUTROPENIA; FEMALE; FEVER; GLIOBLASTOMA; HUMAN; HYPERGLYCEMIA; INFECTION; LIVER DYSFUNCTION; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33646548237     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-2464-5     Document Type: Article

References (19)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics. CA Cancer J Clin 50(1): 7, 2000
2. Stupp R, Mason WP, Van Der Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation tor Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10): 987-996, 2005
3. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1(3): 269, 1995
4. Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985 (Review)
5. Hsiang Y, Hertyzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.J Biol Chem 260(27): 14873-14878, 1985
6. Hertzberg RP, Carafana MJ, Hecht SM: On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28(11): 4629-1638, 1989
7. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246(4933): 1046-1048, 1989
8. Pantazis P, Hinz HR, Mendoza JT, Kozielski AJ, Williams LJ Jr, Stehlin JS Jr, Giovanella BC: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52(14): 3980-3987, 1992
9. Dahut W, Harold N, Takimoto C, Allegra C, Chen A, Hamilton JM, Arbuck S, Sorensen M, Grollman F, Nakashima H, Lieberman R, Liang M, Corse W, Grem J: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14(4): 1236, 1996
10. Dancey J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 74(3): 327, 1996
11. Hochberg F, Grossman SA, Mikkelsen T, Glantz M, Fisher JD, Piantadosi S: Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium. Neuro-Oncol 2(1): 29, 2000
12. Grossman SA, Fisher JD, Piantadosi, Brem H: The new approaches to brain tumor therapy (NABTT) CNS consortium: Organization, objectives, and activities. Cancer Control 5: 107-114, 1998
13. Friedman HS, Petros WP, Friedman AH et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma. Journal of Clinical Oncology 17(5): 1516-1525, 1999
14. Gruber ML, Buster WP: Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27(1): 33-38 2004
15. Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A: Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8(7): 2202-2209, 2002
16. Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E: Phase II study of topotecan in patients with recurrent malignant glioma. National clinical Institute of Canada Clinical Trials Group. Ann Oncol 7(2): 205-207, 1996
17. Burch PA, Bernath AM, Cascino TL et al: A north central cancer treatment group phase II trial of topotecan in relapsed gliomas. Invest New Drugs 18(3): 275-280, 2000
18. Friedman HS, Kerby T, Fields S et al: Topotecan treatment of adults with primary malignant glioma. The brain tumor center at duke. Cancer 85(5): 1160-1165, 1999
19. Keir ST, Hausheer F, Lawless AA, Bigner DD, Friedman HS: Therapeutic activity of 7-[(2-trimethylsilyl)ethyl]-20 (S)-Camptothecin against central nervous tumor-derived xenografts in athymic mice. Cancer Chemother Pharmcol 48(1): 83-87, 2001